Geron
GERN----
Geron (GERN)
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipelin...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Geron Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$4.00183.69%
Forecast & RatingBuy
5analysts
- Strong buy60.00%
- Buy20.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 14 hours ago
Geron reports inducement stock option grants for 202,500 shares at $1.44 each
- PUBT · 23 hours ago
Geron to report Q2 results, host conference call
- Global Report · 1 day ago, 04:18 AM
Cross-Border Spillovers and Domestic Resilience: Supply Chain Friction Signals in US Niche Equities
- Market Beat · Jul 15 at 07:28 AM
What is HC Wainwright's Estimate for Geron FY2027 Earnings?
- Global Report · Jul 15 at 04:14 AM
GDS Supercharges AI Infrastructure Bets as Geron Secures Key FDA Node
- StockTitan · Jul 14 at 07:26 AM
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GERN Stock News
